<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192829</url>
  </required_header>
  <id_info>
    <org_study_id>Thrombosis and cancer.CTIL</org_study_id>
    <nct_id>NCT00192829</nct_id>
  </id_info>
  <brief_title>Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma</brief_title>
  <official_title>Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <brief_summary>
    <textblock>
      The association between cancer and thrombosis is well known and the occurrence of thrombotic
      complications is commonly associated with poor prognosis. The aim os this study is to
      determine the possible value of hypercoagulable parameters as prognostic parameters in
      advanced non-small cell lung carcinoma (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Non-Small Cell Lung Carcinoma</condition>
  <condition>Venous Thromboembolism</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample withdrawal</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of NSCLC.

          -  normal serum bilirubin

          -  informed concent to participate in the study

        Exclusion Criteria:

          -  anticoagulant therapy

          -  infectious disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galit Sarig, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galit Sarig, Ph.D</last_name>
    <phone>+972-4-8543503</phone>
    <email>g_sarig@rambam.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nissim Haim, M.D</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology Laboratory</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galit Sarig, Ph.D</last_name>
      <phone>+972-4-8543523</phone>
      <email>g_sarig@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Galit Sarig, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Institution, Rambam Health Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nissim Haim, M.D</last_name>
      <email>n_haim@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Nissim Haim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001 Feb 1;110(2):91-6.</citation>
    <PMID>11165549</PMID>
  </reference>
  <reference>
    <citation>Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004 Oct;2(10):1760-5.</citation>
    <PMID>15456487</PMID>
  </reference>
  <reference>
    <citation>Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001 Apr;17(4):667-73.</citation>
    <PMID>11401062</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>April 10, 2007</last_update_submitted>
  <last_update_submitted_qc>April 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2007</last_update_posted>
  <keyword>Lung cancer</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Hypercoagulable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

